VERA
$40.53-0.84 (-2.03%)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicep...
Recent News
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.